跳至主要内容
临床试验/NCT00002433
NCT00002433已完成不适用

Activation of Alveolar Macrophages by Aerosolized r-metHuIFN-Gamma (IFN-Gamma) in Patients With AIDS

Amgen1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2001年8月31日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Amgen
入组人数
12
试验地点
1

研究概览

简要总结

To determine safety and tolerance of administering aerosolized recombinant interferon gamma (IFN-gamma) for 4 weeks in patients with AIDS. To examine activation of alveolar macrophages by aerosolized IFN-gamma administration. To determine if subcutaneous (SC) injection of IFN-gamma can activate alveolar macrophages in AIDS patients.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients must have:
  • •Diagnosis of AIDS with one or more opportunistic infections.
  • •Kaposi's sarcoma with prior history of opportunistic infection.
  • •Stable dose of zidovudine (AZT) therapy.
  • •Preserved pulmonary, renal and hepatic function.

排除标准

  • •Co-existing Condition:
  • •Patients with the following conditions or symptoms are excluded:
  • •Presence of active infection.
  • •Active opportunistic infections.
  • •Cardiac disease.
  • •Central nervous system disorders.
  • •History of seizures.
  • •Irreversible airway disease.
  • •Patients with the following are excluded:
  • •Co-existing conditions and symptoms listed in Patient Exclusion Co-existing Conditions.
  • •Prior Medication:
  • •Excluded within 4 weeks of study entry:
  • •Immunosuppressive therapy.
  • •Cytotoxic therapy.
  • •Excluded:
  • •Interferon gamma therapy.

研究者

发起方
Amgen
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验